Page 12 - Service Testing News Today

By Sabela Ojea Shares of Denali Therapeutics on Friday fell after the company said the Phase 2 Himalaya study to treat patients with its amyotrophic lateral...

By Josh Beckerman Shares of G1 Therapeutics fell 46% to $2.44 in after-hours trading on Monday after the company provided an update to its Phase 3...

By Colin Kellaher KalVista Pharmaceuticals on Tuesday said a late-stage study of its proposed sebetralstat therapy for hereditary angioedema hit its key...

By Mike Cherney SYDNEY--Australia-based pharmaceutical company CSL said its Phase 3 study into whether its CSL112 drug reduced the risk of cardiovascular...

By Rob Curran Foghorn Therapeutics shares shot higher after the biotech company said Eli Lilly will conduct clinical trials of one of Foghorn's cancer...

Stock is trading at $28 compared with Eli Lilly’s $739 price tag. That could change if a trial of a pill version of its GLP-1 drug proves effective.

By Ben Glickman Shares of Synlogic fell sharply after the company opted to cease operations after stopping a clinical trial. The stock was down 55% to $1.56...

Health-care companies rose amid promising drug developments. Foghorn Therapeutics shares jumped by 56% after the biotech company said Eli Lilly will conduct...

New clinical trial results from El Lilly suggest its Type 2 diabetes and weight-loss drug, tirzepatide, could upend the incipient market for MASH treatments.

Gilead shares have slid 11.3% since the biotech reported disappointing lung cancer drug trial data on Jan. 22.